October 1, 2020

On Sept. 28, 2020, the Centers for Medicare and Medicaid Services approved the Medicaid state plan amendment to allow Texas HHS to enter into value-based agreements with drug manufacturers based on outcome data or other metrics. Agreements may include things of value, including, but not limited to:

  • Rebate
  • Discount
  • Price reduction
  • Contribution
  • Risk sharing
  • Reimbursement
  • Payment deferral or installment payments
  • Guarantee
  • Patient care
  • Shared savings payments
  • Withholds
  • Bonuses

Drug manufacturers interested in participating in this rebate program should complete and submit the Value-Based Agreement Concept (HHS Form 1402)

Tags: 
Rebates